PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 215 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $835,000 | -37.2% | 100,000 | 0.0% | 0.20% | -37.0% |
| Q2 2023 | $1,330,000 | -4.3% | 100,000 | -16.7% | 0.32% | -10.1% |
| Q1 2023 | $1,389,600 | +41.6% | 120,000 | 0.0% | 0.36% | +33.6% |
| Q4 2022 | $981,600 | +20.7% | 120,000 | -14.3% | 0.27% | +9.4% |
| Q3 2022 | $813,000 | +31.3% | 140,000 | 0.0% | 0.24% | +34.6% |
| Q2 2022 | $619,000 | -51.4% | 140,000 | 0.0% | 0.18% | -46.9% |
| Q1 2022 | $1,274,000 | -59.8% | 140,000 | -9.7% | 0.34% | -59.5% |
| Q4 2021 | $3,171,000 | -31.1% | 155,000 | -13.9% | 0.85% | -42.1% |
| Q3 2021 | $4,599,000 | -26.9% | 180,000 | 0.0% | 1.46% | -23.8% |
| Q2 2021 | $6,295,000 | +5.0% | 180,000 | 0.0% | 1.92% | +0.2% |
| Q1 2021 | $5,996,000 | -42.2% | 180,000 | -55.0% | 1.92% | -40.1% |
| Q4 2020 | $10,376,000 | +49.6% | 400,000 | -43.1% | 3.20% | +26.6% |
| Q3 2020 | $6,938,000 | – | 702,937 | – | 2.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |